8-K: CERo Therapeutics Secures Up to $8 Million in Series D Financing to Advance Immunotherapy Pipeline

CERo Therapeutics Holdings, Inc. announces a securities purchase agreement for a Series D convertible preferred stock transaction, expecting up to $8 million in gross proceeds to advance its engineered T cell therapeutics.

Summary

• CERo Therapeutics Holdings, Inc. has entered into a securities purchase agreement for a Series D convertible preferred stock transaction.
• The gross proceeds are expected to reach up to $8 million, with an initial $5 million expected at the first closing.
• Potential additional closings could bring in up to $3 million, contingent on investor elections.
• The company plans to use the funds to advance its FDA IND allowances in liquid and solid tumors, complete site activation at MD Anderson Cancer Center, and address Nasdaq equity deficiencies.
• The financing aims to extend the company's cash runway and maintain operations.
• The first closing involved the issuance of 6,250 shares of Series D Preferred Stock for approximately $5 million.
• Each share of Series D Preferred Stock has a stated value of $1,000.
• The Series D Preferred Stock ranks senior to Series A and Series B convertible preferred stock, and pari passu with Series C convertible preferred stock.
• Holders of Series D Preferred Stock are entitled to dividends on an as-if converted basis, equal to dividends paid on common stock.
• Each holder of Series D Preferred Stock may convert all, or any part, of the outstanding Series D Preferred Stock, at any time at such holder's option, into shares of the Common Stock at the fixed Conversion Price of $0.78, which is subject to proportional adjustment upon the occurrence of any stock split, stock dividend, stock combination and/or similar transactions.
• The company has agreed to seek stockholder approval for the issuance of Conversion Shares at a conversion price below the Conversion Price.
• If stockholder approval is not obtained by May 31, 2025, the company will file a preliminary Proxy Statement by May 31, 2025, a definitive Proxy Statement by June 30, 2025, and hold a Stockholder Meeting by July 31, 2025.
• Upon any bankruptcy Triggering Event, the Company shall immediately redeem in cash all amounts due under the Series D Preferred Stock at a 25% premium to the greater of (x) the amount of shares of Series D Preferred Stock then outstanding and (y) the equity value of the shares of Series D Preferred Stock then outstanding, unless the holder waives such right to receive such payment.
• The Certificate of Designations contains a variety of obligations on the Company's part not to engage in specified activities.
• The Company will enter into a registration rights agreement to register for resale the Common Stock issuable upon the conversion of the Series D Preferred Stock.
• The Company and holders of Series A and Series C convertible preferred stock will enter into a Consent Agreement to the issuance of the Series D Preferred Stock.

Sentiment

Score: 7

Explanation: The sentiment is cautiously optimistic. The financing is a positive development, but the company still faces challenges related to Nasdaq compliance and clinical trial execution.

Positives

• The financing provides capital to advance clinical trials and expand operations.
• The Series D financing strengthens the company's financial position and extends its cash runway.
• The company believes that it has stockholders equity of $2.5 million requirement as of the date of this filing.
• The company has received FDA IND allowances in liquid and solid tumors.

Negatives

• The company is awaiting a compliance determination from Nasdaq, and there are no assurances regarding the continued listing of the company's common stock and warrants on the Nasdaq Capital Market and the Company could be subject to delisting.
• The company must obtain stockholder approval for certain conversion price adjustments.
• The company is subject to redemption obligations upon bankruptcy.

Risks

• The company's stock and warrants could be subject to delisting from the Nasdaq Capital Market if compliance is not regained.
• The company's future performance is subject to risks outlined in its SEC filings.
• The company's ability to obtain stockholder approval for certain conversion price adjustments is uncertain.
• The company is subject to redemption obligations upon bankruptcy.

Future Outlook

CERo intends to use the net proceeds from the offering to take advantage of the two recent FDA IND allowances in liquid and solid tumors and complete the previously announced site activation at MDACC, as well as bring other sites online quickly. The proceeds will also help to address current Nasdaq deficiencies around Shareholders Equity and extend cash on hand to maintain operations and extend runway. CERo anticipates initiating clinical trials for its lead product candidate, CER-1236, in 2025 for hematological malignancies.

Management Comments

• Chris Ehrlich, Chief Executive Officer, stated that the company is gratified by the support it has received from investors and looks forward to continued execution and progress.

Industry Context

The announcement reflects ongoing investment in the immunotherapy sector, particularly in companies developing engineered T cell therapies. CERo's focus on phagocytic mechanisms and CER-T cells positions it within the next generation of cell therapy approaches.

Comparison to Industry Standards

• The Series D financing is a common funding mechanism for biotechnology companies in the clinical development stage.
• Comparable companies in the cell therapy space, such as Kite Pharma (acquired by Gilead), Juno Therapeutics (acquired by Celgene), and Adaptimmune, have also raised significant capital through private and public offerings to fund research and development.
• The specific terms of the Series D financing, including the conversion price and redemption features, are typical for preferred stock transactions in the biotech industry, designed to attract investors while providing downside protection.
• The company's plan to use the proceeds to advance clinical trials and address Nasdaq compliance issues aligns with the priorities of other publicly traded biotech companies facing similar challenges.

Stakeholder Impact

• Shareholders: Potential dilution from the issuance of new shares, but also potential upside from clinical trial progress.
• Employees: Continued employment and potential for growth as the company advances its pipeline.
• Customers: Potential for new and improved cancer therapies.
• Suppliers: Continued business relationships and potential for increased demand.
• Creditors: Improved financial stability and ability to meet obligations.

Next Steps

• Complete the initial closing of the Series D financing.
• Advance clinical trials for CER-1236 in hematological malignancies.
• Complete site activation at MD Anderson Cancer Center and bring other sites online.
• Address Nasdaq equity deficiencies and regain compliance.
• Obtain stockholder approval for potential conversion price adjustments.
• File a registration statement with the SEC to register for resale the Common Stock issuable upon the conversion of the Series D Preferred Stock.

Key Dates

Keywords

Series D Financing, Convertible Preferred Stock, Immunotherapy, Engineered T Cell Therapeutics, Clinical Trials, Nasdaq Compliance, CERo Therapeutics, Capital Raise